Inozyme Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

• Inozyme Pharma Inc INZY.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -33 cents. The mean expectation of nine analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -47 cents to -33 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Inozyme Pharma Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $27.07 million.

• Inozyme Pharma Inc shares had fallen by 58.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Inozyme Pharma Inc is $15.50

This summary was machine generated from LSEG data March 10 at 04:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)